» Articles » PMID: 31779269

HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2019 Nov 30
PMID 31779269
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor worldwide; however, the traditional therapeutic approaches and survival rates are still limited. To improve current therapies, it is necessary to investigate the molecular mechanisms underlying liver cancer and to identify potential therapeutic targets. The aims of this study were to verify the mechanisms and therapeutic potential of the ketogenesis rate-limiting enzyme 3-Hydroxymethylglutaryl-CoA synthase 2 (HMGCS2) in HCC. Immunohistochemical staining of human liver disease tissue arrays showed that HMGCS2 is abundantly expressed in normal liver tissues but is downregulated in cirrhosis and HCC tissues. In HCC patients, lower HMGCS2 expression was correlated with higher pathological grades and clinical stages. In our investigation of the molecular mechanisms of HMGCS2 in HCC, we showed that knockdown of HMGCS2 decreased ketone production, which promoted cell proliferation, cell migration, and xenograft tumorigenesis by enhancing c-Myc/cyclinD1 and EMT signaling and by suppressing the caspase-dependent apoptosis pathway. Ketone body treatment reduced the proliferation- and migration-promoting effects of HMGCS2 knockdown in cells. In contrast, HMGCS2 overexpression increased the intracellular ketone level and inhibited cell proliferation, cell migration, and xenograft tumorigenesis. Finally, ketogenic diet administration significantly inhibited liver cancer cell growth in mice. Our studies highlight the potential therapeutic strategy of targeting HMGCS2-mediated ketogenesis in liver cancer.

Citing Articles

Deciphering Colorectal Cancer-Hepatocyte Interactions: A Multiomics Platform for Interrogation of Metabolic Crosstalk in the Liver-Tumor Microenvironment.

Nelson A, Reese L, Rono E, Queathem E, Qiu Y, McCluskey B Int J Mol Sci. 2025; 26(5).

PMID: 40076609 PMC: 11900982. DOI: 10.3390/ijms26051976.


Discovery of PPAR Alpha Lipid Pathway Modulators That Do Not Bind Directly to the Receptor as Potential Anti-Cancer Compounds.

Al Subait A, Alghamdi R, Ali R, Alsharidah A, Huwaizi S, Alkhodier R Int J Mol Sci. 2025; 26(2).

PMID: 39859448 PMC: 11766124. DOI: 10.3390/ijms26020736.


Comprehensive Overview of Ketone Bodies in Cancer Metabolism: Mechanisms and Application.

Liang Z, Deng L, Zhou X, Zhang Z, Zhao W Biomedicines. 2025; 13(1).

PMID: 39857793 PMC: 11760447. DOI: 10.3390/biomedicines13010210.


Ketogenic diet and cancer: multidimensional exploration and research.

Wan S, Zhou X, Xie F, Zhou F, Zhang L Sci China Life Sci. 2025; .

PMID: 39821829 DOI: 10.1007/s11427-023-2637-2.


Mitochondrial Gene Scoring System: Predicting Prognosis and Precision Therapy for TACE Non-Response in Hepatocellular Carcinoma Patients.

Ma J, Wei W, Wang Y, Zhao Z, Xiong Z, Mei J J Cancer. 2025; 16(2):629-647.

PMID: 39744494 PMC: 11685679. DOI: 10.7150/jca.103946.


References
1.
Paoli A, Rubini A, Volek J, Grimaldi K . Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr. 2013; 67(8):789-96. PMC: 3826507. DOI: 10.1038/ejcn.2013.116. View

2.
Martinez-Outschoorn U, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti M . Ketone body utilization drives tumor growth and metastasis. Cell Cycle. 2012; 11(21):3964-71. PMC: 3507492. DOI: 10.4161/cc.22137. View

3.
Wang J, Shidfar A, Ivancic D, Ranjan M, Liu L, Choi M . Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. Int J Cancer. 2017; 140(11):2484-2497. DOI: 10.1002/ijc.30680. View

4.
Camarero N, Mascaro C, Mayordomo C, Vilardell F, Haro D, Marrero P . Ketogenic HMGCS2 Is a c-Myc target gene expressed in differentiated cells of human colonic epithelium and down-regulated in colon cancer. Mol Cancer Res. 2006; 4(9):645-53. DOI: 10.1158/1541-7786.MCR-05-0267. View

5.
Grabacka M, Wilk A, Antonczyk A, Banks P, Walczyk-Tytko E, Dean M . Fenofibrate Induces Ketone Body Production in Melanoma and Glioblastoma Cells. Front Endocrinol (Lausanne). 2016; 7:5. PMC: 4735548. DOI: 10.3389/fendo.2016.00005. View